Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03511222 · ClinicalTrials.gov registry record · Phase 1
Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors
A Phase 1 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT03511222 is a Phase 1 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 16 participants.
The verdict
NCT03511222, a Phase 1 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The investigators hypothesize that vorolanib in combination with checkpoint inhibitors (pembrolizumab for gastric/gastroesophageal (GE) junction cancers and nivolumab for hepatocellular carcinoma (HCC)) may improve immunotherapy efficacy by overcoming treatment resistance of checkpoint inhibitors in gastrointestinal (GI) cancers.
Interventions
- DRUG Pembrolizumab
- DRUG Nivolumab
- DRUG Vorolanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2018-09-11 |
| Est. Completion | 2020-05-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03511222
The ClinicalTrials.gov registry entry for NCT03511222 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT03511222 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03511222 about?
NCT03511222 is a clinical study titled "Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors". The investigators hypothesize that vorolanib in combination with checkpoint inhibitors (pembrolizumab for gastric/gastroesophageal (GE) junction cancers and nivolumab for hepatocellular carcinoma (HCC)) may improve immunotherapy efficacy by overcoming treatment resistance of checkpoint inhibitors in...
What is the current status of trial NCT03511222?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2018-09-11. Estimated completion is 2020-05-28.
What interventions are being tested in trial NCT03511222?
The interventions under investigation include: Pembrolizumab (DRUG), Nivolumab (DRUG), Vorolanib (DRUG).
Who is sponsoring clinical trial NCT03511222?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.